This invention pertains generally to systems and methods for detecting the yeast Candida auris (“C. auris”). More specifically, the invention is directed to the composition and use of yeast growth media that selectively supports or deters the growth of C. auris relative to other species of fungi.
C. auris has emerged as a novel organism causing infections in hospital settings. It is rapidly developing into a global threat. According to the Centers for Disease Control and Prevention (CDC): “Candida auris is an emerging fungus that presents a serious global health threat.” CDC, Candida auris, www.cdc.gov/fungal/diseases/candidiasis/Candida-auris.html. Within a period of only 7 years, the organism has caused healthcare-associated outbreaks in four continents. See, e.g., European Centre for Disease Prevention and Control, Candida auris in Healthcare Settings—Europe (Dec. 19, 2016), available at ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Candida-in-healthcare-settings_19-Dec-2016.pdf; A. Chowdhary et al., Candida auris: a Rapidly Emerging Cause of Hospital-Acquired Multidrug-Resistant Fungal Infections Globally, 13(5) PLoS Pathogens e1006290 (May 18, 2017), available at journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006290; C. J. Clancy and M. N. Nguyen, Emergence of Candida auris: An International Call to Arms, 64 Clinical Infectious Diseases 141-143 (January 2017), available at doi.org/10.1093/cid/ciw696; M. Bougnoux et al., Healthcare-Associated Fungal Outbreaks: New and Uncommon Species, New Molecular Tools for Investigation and Prevention, 7:45 Antimicrobial Resistance & Infection Control (Mar. 27, 2018), available at doi.org/10.1186/s13756-018-0338-9. For example, major outbreaks were reported in Spain (33 bloodstream infections in a surgical ICU unit) and London (50 cases in a cardiothoracic center). S. Schelenz et al., First Hospital Outbreak of the Globally Emerging Candida auris In a European Hospital, 5:35 Antimicrobial Resistance & Infection Control (Oct. 19, 2016), available at doi.org/10.1186/s13756-016-0132-5. As of Jul. 31, 2018, there were more than 350 confirmed cases of C. auris infection in the US, with the majority of cases located in New York and New Jersey. CDC, Tracking Candida auris, www.cdc.gov/fungal/diseases/candidiasis/tracking-c-auris.html.
C. auris is prone to be spread in hospital settings and there are indications that it is becoming more widely established. In India, for example, C. auris at one point accounted for 5% of cases of candidemia acquired in intensive care units. A. Chakrabarti et al., Incidence, Characteristics and Outcome of ICU-Acquired Candidemia In India, 41 Intensive Care Medicine 285-295 (February 2015), available at link.springer.com/article/10.1007/s00134-014-3603-2. The species “has caused outbreaks in healthcare settings.” CDC, Candida auris, www.cdc.gov/fungal/diseases/candidiasis/Candida-auris.html.
C. auris infections are dangerous and difficult to treat. C. auris has the potential to be multi-drug resistant—isolates have been detected that are resistant to all major classes of antifungal agents. Thus, it is difficult to treat a C. auris infection. CDC, Candida auris, www.cdc.gov/fungal/diseases/candidiasis/Candida-auris.html. Invasive infections with C. auris currently carry a high mortality (30-60%), even if receiving treatment. See, e.g., CDC, Fact Sheet, www.cdc.gov/fungal/diseases/candidiasis/c-auris-drug-resistant.html (“More than 1 in 3 patients with invasive C. auris infection . . . die.”); S. E. Morales-López et al., Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia, 23 Emerging Infectious Diseases 162-164 (January 2017), available at. dx.doi.org/10.3201/eid2301.161497; C. J. Clancy and M. H. Nguyen, Emergence of Candida auris: An International Call to Arms, 64 Clinical Infectious Diseases 141-143 (January 2017), available at doi.org/10.1093/cid/ciw696; S. R. Lockhart et al., Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses, 64 Clinical Infectious Diseases 134-140 (January 2017), available at doi.org/10.1093/cid/ciw691.
Because of the danger posed by C. auris, early detection is important. See, e.g., CDC, Candida auris,www.cdc.gov/fungal/diseases/candidiasis/Candida-auris.html (“it is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread”); European Centre for Disease Prevention and Control, Candida auris in Healthcare Settings—Europe (Dec. 19, 2016), available at ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Candida-in-healthcare-settings_19-Dec-2016.pdf. The need for early detection in a patient or a hospital environment is even more urgent since C. auris can persist on moist or dry surfaces in a hospital environment for at least 7-30 days. C. Piedrahita et al., Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species, 38 Infection Control & Hospital Epidemiology 1107-1109 (September 2017), available at doi.org/10.1017/ice.2017.127; A. Abdolrasouli et al., In Vitro Efficacy of Disinfectants Utilised for Skin Decolonization and Environmental Decontamination During a Hospital Outbreak With Candida Auris, 60 Mycoses 758-763 (2017), available at doi.org/10.1111/myc.12699.
Unfortunately, C. auris is not easy to identify and is prone to misdiagnosis by conventional methods. CDC, Candida auris, cdc.gov/fungal/diseases/candidiasis/Candida-auris.html. The CDC note that C. auris “is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology.” Id. Indeed, traditional detection methods result in “common misidentifications based on the identification method used.” CDC, Recommendations for Identification of Candida auris, www.cdc.gov/fungal/diseases/candidiasis/recommendations.html; see also, S. Kathuria et al., Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method, 53 Journal of Microbiology 1823-1830 (June 2015), available at jcm.asm.org/content/53/6/1823.full.pdf+html; A. Chowdhary et al., Candida auris: a Rapidly Emerging Cause of Hospital-Acquired Multidrug-Resistant Fungal Infections Globally, 13(5) PLoS Pathogens e1006290 (May 18, 2017), available at journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006290.
The state-of-the-art yeast-detection systems either fail to adequately identify C. auris (because of common misidentifications) or they are expensive and cumbersome to use. They fail to timely identify the presence—and threat—of C. auris. The failings in the detection systems and the multi-drug-resistant nature of Candida auris threaten dangerous outbreaks of Candida auris infections. Currently, no simple detectable markers for the presence of C. auris are known. In the near future, PCR-based methods may be available to detect the presence of C. auris DNA quickly and accurately. However, this method does not allow the distinction between dead and viable (i.e., colony-forming) cells and does not provide the cells for further investigation, e.g. analysis of their drug resistance (which is important for therapy) or their genetic makeup.
Accordingly, there is a need for a means to accurately and timely identify viable C. auris and to isolate those cells for further study.
The present invention is directed to systems and methods to identify and isolate viable C. auris based on C. auris's distinctive and tailorable sensitivity to certain compounds. As discovered as part of this research, C. auris generally shows a higher resistance to Quaternary Ammonium Compound (“QACs”) than do other yeasts. If compared to most other yeasts, the difference in resistance increases at higher temperatures (e.g., the difference in resistance is greater at 37° C.-38.5° C. than it is at 30° C.). Thus, a QAC-containing culture medium generally allows the growth of C. auris cells into colonies while suppressing the growth of other yeast colonies, and thereby acts as a positive-selection system for C. auris. The yeast-supplement mixture in the culture medium may be formulated to change C. auris's resistance to a QAC relative to other yeasts' resistance to a QAC. For many yeasts, a nutritionally-poor-and-defined yeast-supplement mixture will increase C. auris's relative resistance compared to a nutritionally-rich-and-complex yeast-supplement mixture. C. auris also generally shows a lower resistance to tert-Butyl-hydroperoxide (“tBHP”) than do other yeasts. Thus, a tBHP-containing culture medium generally suppresses growth of C. auris colonies while allowing the growth of other yeast colonies, and thereby acts as negative-selection system for C. auris.
In one aspect of the invention, a C. auris positive-selection culture medium includes a QAC, a sugar, and a yeast supplement. Exemplary QACs include cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, and tetradecyltrimethylammonium bromide. The culture medium may include a solidifying agent such as agar, when solid-medium-based assays (e.g., plate assays) are desired. The culture medium may include a nutritionally poor (without amino acids) and defined yeast-supplement mixture or it may include a nutritionally rich (with amino acids) and complex yeast-supplement mixture. The yeast-supplement mixture may be used to tailor the relative sensitivity of C. auris to the QAC (relative to other organisms). An antibiotic may be included in the medium. The positive-selection culture medium may be used for culturing C. auris while suppressing the growth of other microorganisms.
In another aspect of the invention, a method for detecting C. auris includes inoculating a QAC-based C. auris positive-selection culture medium with a sample and incubating the inoculated medium at a temperature above the standard yeast-incubation temperature (e.g., ˜36.5° C.-39.0° C. versus the standard ˜30° C.). The growth of cultures in such an assay suggests the presence of C. auris in the sample.
In another aspect of the invention, a method for detecting C. auris includes use of two different positive-selection media. The method includes inoculating a QAC-based C. auris positive-selection culture medium containing a nutritionally poor yeast supplement with a sample, incubating the inoculated medium at a temperature above the standard yeast-incubation temperature, collecting a sample from cultures grown on the incubated medium, inoculating a QAC-based C. auris positive-selection culture medium containing a nutritionally rich yeast supplement with the culture sample, incubating the inoculated medium at a temperature above the standard yeast-incubation temperature. The growth of cultures on the second incubated medium (the nutritionally rich medium) in such an assay suggests the presence of C. auris in the sample.
In another aspect of the invention, a method for detecting C. auris includes combining a C. auris positive-selection-culture-medium-based assay with a C. auris negative-selection-culture-medium-based assay. The positive-selection medium includes a QAC. The negative selection medium includes tBHP. The positive-selection culture medium supports the growth of C. auris while suppressing the growth of other microorganisms. The negative-selection culture medium suppresses the growth of C. auris while supporting the growth of other microorganisms. Growth of yeast cultures on a positive-selection culture medium after incubation at an elevated temperature (relative to the standard yeast-incubation temperature) suggests the presence of C. auris. Growth of yeast cultures on a negative-selection culture medium after incubation at the standard yeast-incubation temperature suggests the absence of C. auris. The assays may be performed on a common sample (e.g., a wipe of a surface in a hospital) in parallel: cultures on the positive-selection medium combined with no cultures on the negative-selection medium suggests the presence of C. auris. The assays may also be performed in sequence, with samples from the cultures grown on a positive-selection medium being used to inoculate a negative selection medium (perhaps with intervening culturing on a nonselective culture medium or a different positive-selection culture medium). The combination of positive-selection and negative-selection assays may provide more certain identification of C. auris than either assay alone.
These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description, appended claims, and accompanying drawings where:
In the summary above, and in the description below, reference is made to particular features of the invention in the context of exemplary embodiments of the invention. The features are described in the context of the exemplary embodiments to facilitate understanding. But the invention is not limited to the exemplary embodiments. And the features are not limited to the embodiments by which they are described. The invention provides a number of inventive features which can be combined in many ways, and the invention can be embodied in a wide variety of contexts. Unless expressly set forth as an essential feature of the invention, a feature of a particular embodiment should not be read into the claims unless expressly recited in a claim.
Except as explicitly defined otherwise, the words and phrases used herein, including terms used in the claims, carry the same meaning they carry to one of ordinary skill in the art as ordinarily used in the art.
Because one of ordinary skill in the art may best understand the structure of the invention by the function of various structural features of the invention, certain structural features may be explained or claimed with reference to the function of a feature. Unless used in the context of describing or claiming a particular inventive function (e.g., a process), reference to the function of a structural feature refers to the capability of the structural feature, not to an instance of use of the invention.
Except for claims that include language introducing a function with “means for” or “step for,” the claims are not recited in so-called means-plus-function or step-plus-function format governed by 35 U.S.C. § 112(f). Claims that include the “means for [function]” language but also recite the structure for performing the function are not means-plus-function claims governed by § 112(f). Claims that include the “step for [function]” language but also recite an act for performing the function are not step-plus-function claims governed by § 112(f).
Except as otherwise stated herein or as is otherwise clear from context, the inventive methods comprising or consisting of more than one step may be carried out without concern for the order of the steps.
The terms “comprising,” “comprises,” “including,” “includes,” “having,” “haves,” and their grammatical equivalents are used herein to mean that other components or steps are optionally present. For example, an article comprising A, B, and C includes an article having only A, B, and C as well as articles having A, B, C, and other components. And a method comprising the steps A, B, and C includes methods having only the steps A, B, and C as well as methods having the steps A, B, C, and other steps.
Terms of degree, such as “substantially,” “about,” and “approximately,” are used herein to denote features that satisfy their technological purpose equivalently to a feature that is “exact.” For example, a component A is “substantially” perpendicular to a second component B if A and B are at an angle such as to equivalently satisfy the technological purpose of A being perpendicular to B.
Except as otherwise stated herein, or as is otherwise clear from context, the term “or” is used herein in its inclusive sense. For example, “A or B” means “A or B, or both A and B.”
In the culture assays depicted herein, (e.g.,
The invention is premised on the discovery that C. auris has two distinctive phenotypes: First, C. auris is relatively more resistant to quaternary ammonium compounds (“QACs” or “quats”) when compared to other yeasts. This relative resistance increases at higher temperatures (other yeasts show a decreased resistance at higher temperature while C. auris remains approximately the same). And a difference in relative sensitivity to a particular QAC between C. auris and another yeast can be enhanced by choosing a particular kind of growth-factor supplement (for example, Yeast Nitrogen Base vs. peptone). Second, C. auris is relatively less resistant to tert-butyl-hydroperoxide (“tBHP”) when compared to other yeasts. Utilizing these relative sensitivities, identification of C. auris is improved through use of a culture medium that allows C. auris growth while suppressing other yeasts (“positive selection”) and a culture medium that suppresses C. auris growth while allowing the growth of other yeasts (“negative selection”).
Positive-Selection System: C. auris has a high degree of relative resistance towards QACs, such as cetylpyridinium chloride. The same is true for C. haemulonii which (together with C. lusitaniae and C. krusei) is the closest relative to C. auris. The closely-related Candida species can be distinguished, however, by their differential QAC resistance at higher-than-standard yeast incubation temperatures (preferably in the range of 37° C.-38.5° C. vs the standard 30° C.). Besides cetylpyridinium chloride, other QACs, including benzalkonium chloride, benzethonium chloride, and tetradecyltrimethylammonium bromide were successfully used to differentiate C. auris from other Candida species. As an added benefit, growth of many bacteria and molds is suppressed at the applied QAC concentrations. This makes this system an appealing choice for positive selection of C. auris within a sample containing mixed microbial species (e.g. a sample wiped from human skin).
Discriminating Candida species based on their relative sensitivity to QACs is a novel approach to identifying C. auris. QACs are known to be relatively ineffective in suppressing or killing Candida species. Using short-term exposure, activity of QACs has been described as generally weak in various Candida species. See, e.g., J. L. Cadnum et al., Effectiveness of Disinfectants Against Candida auris and Other Candida Species, 38 Infection Control & Hospital Epidemiology 1240-1243 (October 2017), available at doi.org/10.1017/ice.2017.162. But differential sensitivity of colony formation ability among different Candida species to QACs added to growth media is largely unexplored. Using this discriminating phenotype is a novel and effective way to identify C. auris. Further, using the temperature and growth factor supplement dependence of the relative sensitivity to QACs is a novel and effective way to identify C. auris. This relative sensitivity is the basis for positive selection media for C. auris.
The plating scheme for the
Yeasts were first streaked on Sabouraud-dextrose agar plates and pre-grown at 30° C. for 72 hours. Suspensions were made and adjusted to 2.5×107 cells per ml and subjected to serial 1:10 dilutions. Drops were placed on solid agar plates of Sabouraud dextrose (4% dextrose and 10 g/l peptone) which contained various amounts of cetylpyridinium chloride that were added after autoclaving from a 2% stock solution in isopropanol.
As shown, after 48 hours of incubation at 30° C., C. glabrata, C. krusei, and S. cerevisiae are most sensitive whereas C. auris and C. haemulonii are the most resistant species. As the amount of cetylpyridinium chloride in the medium increases (top to bottom in the figure), all but C. auris and C. haemulonii are suppressed. These two species cannot be distinguished one from the other on the data presented. Notably, C. auris is frequently misidentified as C. haemulonii in the VITEK identification system. S. Kathuria et al., Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method, 53 Journal of Microbiology 1823-1830 (June 2015), available at jcm.asm.org/content/53/6/1823.full.pdf+html. Thus, the QAC-containing medium alone may not entirely resolve the misidentification problems of the prior art, though research is ongoing.
After 48 hours of incubation at 38.5° C., however, C. haemulonii shows an increased sensitivity to cetylpyridinium chloride relative to C. auris (the opposite is found for C. albicans). Thus, C. auris can be distinguished from C. haemulonii. It should be noted that C. auris, unlike many other yeasts, is known to be able to grow at high temperatures (42° C. and above) but 38.5° C. is a temperature that still fully supports the growth of all tested yeast strains if untreated with cetylpyridinium chloride. Thus, the positive selection medium is based on the relative cetylpyridinium chloride resistance of C. auris at elevated temperatures.
A recipe for an exemplary positive-selection medium is as follows: Mix per one liter of deionized water (all % in weight/volume, subject to normal laboratory uncertainty): (1) a solidifying agent if procedure done on plates: 2% agar; (2) a sugar: 4% dextrose (autoclave separately, add after autoclaving); (3) a supplement mix: 0.7% Yeast Nitrogen Base with ammonium sulfate (commercial mix, autoclave separately, add after autoclaving); and (4) a Quaternary Ammonium Compound (all stocks dissolved at 2% in 91% isopropanol, add after autoclaving): cetylpyridinium chloride=8.5 ml or benzalkonium chloride=13 ml or tetradecyltrimethylammonium bromide=13 ml. It is possible to use other supplements such as peptone but there are differences, e.g. yeast extract is not recommended. As shown below, the nature of the supplement may critically modulate QAC sensitivity in a species-specific manner to improve positive selection of C. auris. Variations in ingredients may also improve the initial selection of C. auris within samples that may contain a multitude of other microorganisms which need to be suppressed. For example, the following adaptations (alone or in combinations) may be implemented: (1) Add extra isopropanol (or dissolve the QAC at a lower concentration in isopropanol). Could go up to 3%. C. auris of approximately 1-12 days of culture age is very resistant to isopropanol but many other organisms are not. This approach may not be appropriate if it is possible that older C. auris is present because C. auris of about 12-days of culture age or older is less resistant to isopropanol than is younger C. auris. (2) Lower the amount of Yeast Nitrogen Base. Can go down to 0.14% which makes the medium less rich. This is no problem for C. auris but fewer organisms will grow. (3) Add 25 μg/ml chloramphenicol (stock: 50 mg/ml in ethanol, a standard method to suppress bacteria). Samples are placed on solid media by, for example, streaking or dropping suspension. The inoculated medium is incubated at approximately 38.5° C. and evaluated after as early as 36 hours, preferably after about 48 to 60 hours.
Two-Step Positive-Selection System: In circumstances potentially involving old C. auris cells (e.g., 12 days old or older) or certain other yeasts such as Candida lusitaniae and certain strains of Saccharomyces cerevisiae, it is preferable to use a two-step process at 37° C. The first step involves a first positive-selection medium (the “Step-1 Medium”) that has been modified to the allow uninhibited growth of colonies from old C. auris cells which may be of concern in the surveillance of surface contamination (e. g. in hospitals). Type and concentration of QAC are selected to minimize impact on old C. auris cells, isopropanol is not used as a solvent, and the incubation temperature is 37° C. This Step-1 Medium may not, however, uniquely select C. auris. For example, C. lusitaniae and certain strains of S. cerevisiae may grow on or in such a medium, even when incubated at an elevated temperature (e.g., 37° C.). The second step involves a second positive-selection medium (the “Step-2 Medium”) and cells cultured with the first medium. Because the cells for the second step come from the colonies formed in the first step, the risk of failing to detect C. auris because of the age of the cells is not present. The Step-2 Medium is formulated to suppress growth of C. lusitaniae and S. cerevisiae when incubated at an elevated temperature (e.g., 37° C.). Thus, the Step-2 Medium is designed to positively uniquely select C. auris without concern for the age of the cells. Together, the Step-1 Medium and the Step-2 Medium positively select for C. auris without significant loss of old C. auris cells and without significant risk of misidentification of another yeast as C. auris. Other organisms are also efficiently suppressed (as outlined below).
A Step-1 Medium includes: (1) a higher dextrose content (relative to standard media) to inhibit bacterial growth, (2) an antibiotic to inhibit bacterial growth, (3) a nutritionally poor (with no amino acids) and defined supplement mixture to inhibit growth of bacteria, yeast, and molds with complex growth requirements, and (4) a QAC or a combination of more than one QAC to generally suppress the growth of organisms other than C. auris.
An exemplary recipe for a solid Step-1 Medium is as follows: Mix per one liter of deionized water: (1) 20 g agar; (2) 60 g dextrose (add from 200 g/l stock solution after autoclaving); (3) 25 mg chloramphenicol (add from a 50 mg/ml stock in ethanol after autoclaving); (4) 6.7 g Yeast Nitrogen Base without amino acids and with ammonium sulfate (YNB) (add from 67 g/l stock in water after autoclaving); (5) 70 mg benzalkonium chloride (add from a 10 mg/ml stock in water after autoclaving); and (6) 80 mg tetradecyltrimethylammonium bromide (add from a 20 mg/ml stock in water after autoclaving).
As shown in
As shown in
Two other tests of Step-1 Medium are depicted in
Step-2 Medium includes: (1) a higher dextrose content (relative to standard media) to inhibit bacterial growth, (2) an antibiotic to inhibit bacterial growth, (3) a nutritionally rich (with amino acids) and complex supplement mixture to modulate the C. auris QAC sensitivity vis-à-vis YNB, and (4) a QAC or a combination of more the one QAC to suppress the growth of organisms other than C. auris (including by suppressing C. lusitaniae and S. cerevisiae).
An exemplary recipe for solid Step-2 Medium is as follows: Mix per one liter of deionized water: (1) 20 g agar; (2) 60 g dextrose (add from 200 g/l stock solution after autoclaving); (3) 25 mg chloramphenicol (add from a 50 mg/ml stock in ethanol after autoclaving); (4) 10 g peptone (meat); and (5) 130 mg benzalkonium chloride (add from a 10 mg/ml stock in water after autoclaving).
Tests of Step-2 Medium are depicted in
There are two points of note from the tests depicted in
Negative Selection System: C. auris has a relatively high sensitivity to the oxidizing agent tert-butyl-hydroperoxide (“tBHP”). Hence, tBHP can be used as the basis of a negative-selection medium.
In use of a negative-selection medium, samples are added to the medium by, for example, streaking or dropping suspension. The inoculated medium is incubated at approximately 30° C. and evaluated after 22-26 hours. The accuracy and robustness of such an assay may be improved by first culturing the samples on a non-selective medium, such as a standard Sabouraud-dextrose medium, and then taking samples from the cultures and applying to the negative-selection medium. For example, samples may be placed on a standard medium, incubated at 30° C. for 24-48 hours, and then samples of the cultures placed on the negative-selection medium and incubated at 30° C. for about 24 hours. Lack of growth on the negative-selection medium indicates the samples are C. auris (or C. tropicalis, if that yeast is not first eliminated by, e.g., use of a positive-selection medium).
A recipe for an exemplary negative-selection medium is as follows: Mix per one liter of deionized water (all % in weight/volume, subject to normal laboratory uncertainty): (1) a solidifying agent if procedure done on plates: 2% agar; (2) a sugar: 4% dextrose (autoclave separately, add after autoclaving); (3) a supplement mix: 1% peptone; and (4) the oxidizing agent tert-butyl-hydroperoxide (tBHP): 350 μl (from a 70% solution in water, add after autoclaving).
Another recipe for an exemplary solid negative-selection medium is as follows: Mix per one liter of deionized water: (1) 20 g agar; (2) 60 g dextrose (add from 200 g/l stock solution after autoclaving); (3) 25 mg chloramphenicol (add from a 50 mg/ml stock in ethanol after autoclaving); (4) 20 g tryptone; and (5) 300 μl tert-butyl-hydroperoxide (add from 70% solution in water after autoclaving).
As depicted in the exemplary flow charts of
An assay using a defined-supplement QAC-based positive-selection medium and a complex-supplement QAC-based positive-selection medium is depicted in
The assay illustrated in
While the steps of the exemplary assays depicted in
Another exemplary parallel assay would include a first step of inoculating and incubating a defined-supplement QAC-based positive-selection medium, as described above with reference to items 1801 to 1811 in
Exemplary Applications. The positive/negative selection systems may be most valuable in monitoring of patient/visitor/staff colonization or environmental contamination in a hospital environment and lends itself to large-scale testing. Such monitoring and, if needed, epidemiological investigation and source identification, is of particular importance for C. auris which shows a high propensity for patient-to-patient transmission. The positive/negative selection systems may be especially important in a healthcare setting in a less-developed country where sophisticated diagnostics are not readily available. Initial clues to the nature of the pathogen can thus be obtained, leading to more targeted testing. The positive/negative selection systems may be incorporated in automated diagnostic systems, such as VITEK, that use similar metabolic and growth criteria. This would aid accurate identification of C. auris.
While the foregoing description is directed to the preferred embodiments of the invention, other and further embodiments of the invention will be apparent to those skilled in the art and may be made without departing from the basic scope of the invention. And features described with reference to one embodiment may be combined with other embodiments, even if not explicitly stated above, without departing from the scope of the invention. The scope of the invention is defined by the claims which follow.
This application claims the benefit of U.S. Provisional Application No. 62/667,534, filed on May 6, 2018, the entirety of which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
20150299647 | Akada | Oct 2015 | A1 |
Number | Date | Country |
---|---|---|
106748240 | May 2017 | CN |
43020720 | Sep 1968 | JP |
Entry |
---|
European Centre for Disease Prevention and Control, Candida auris in Healthcare Settings—Europe (Dec. 19, 2016), available at https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Candida-in-healthcare-settings_19-Dec-2016.pdf. |
A. Chowdhary et al., Candida auris: a Rapidly Emerging Cause of Hospital-Acquired Multidrug-Resistant Fungal Infections Globally, 13(5) PLoS Pathogens e1006290 (May 18, 2017), available at http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006290. |
C.J. Clancy and M.H. Nguyen, Emergence of Candida auris: An International Call to Arms, 64 Clinical Infectious Diseases 141-143 (Jan. 2017), available at https://doi.org/10.1093/cid/ciw696. |
M. Bougnoux et al., Healthcare-Associated Fungal Outbreaks: New and Uncommon Species, New Molecular Tools for Investigation and Prevention, 7:45 Antimicrobial Resistance & Infection Control (Mar. 27, 2018), available at https://doi.org/10.1186/s13756-018-0338-9. |
S. Schelenz et al., First Hospital Outbreak of the Globally Emerging Candida auris in a European Hospital, 5:35 Antimicrobial Resistance & Infection Control (Oct. 19, 2016), available at https://doi.org/10.1186/s13756-016-0132-5. |
A. Chakrabarti et al., Incidence, Characteristics and Outcome of ICU-Acquired Candidemia in India, 41 Intensive Care Medicine 285-295 (Feb. 2015), available at https://link.springer.com/article/10.1007/s00134-014-3603-2. |
S. E. Morales-López et al., Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia, 23 Emerging Infectious Diseases 162-164 (Jan. 2017), available at. https://dx.doi.org/10.3201/eid2301.161497. |
S.R. Lockhart et al., Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses, 64 Clinical Infectious Diseases 134-140 (Jan. 2017), available at https://doi.org/10.1093/cid/ciw691. |
C. Piedrahita et al., Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species, 38 Infection Control & Hospital Epidemiology 1107-1109 (Sep. 2017), available at https://doi.org/10.1017/ice.2017.127. |
A. Abdolrasouli et al., In Vitro Efficacy of Disinfectants Utilised for Skin Decolonization and Environmental Decontamination During a Hospital Outbreak With Candida Auris, 60 Mycoses 758-763 (2017), available at https://doi.org/10.1111/myc.12699. |
S. Kathuria et al., Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method, 53 Journal of Microbiology 1823-1830 (Jun. 2015), available at http://jcm.asm.org/content/53/6/1823.full.pdf+html. |
J.L. Cadnum et al., Effectiveness of Disinfectants Against Candida auris and Other Candida Species, 38 Infection Control & Hospital Epidemiology 1240-1243 (Oct. 2017), available at https://doi.org/10.1017/ice.2017.162. |
Sexton, D.J. et al. (2018) Direct Detection of Emergent Fungal Pathogen Candida auris in Clinical Skin Swabs by SYBR Green-Based Quantitative PCR Assay. J Clin Microbiol 56 (12). |
Jeffery-Smith, A. et al. (2018) Candida auris: a Review of the Literature. Clin Microbiol Rev 31 (1). |
Suleyman, G. and Alangaden, G.J. (2016) Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention. Infect Dis Clin North Am 30 (4), 1023-1052. |
Walker, E. (2003) Quaternary ammonium compounds. In Handbook of Topical Antimicrobials—Industrial Applications in Consumer Products and Pharmaceuticals (Paulson, D. ed), pp. 99-116, Marcel Dekker, Inc. |
Mizusawa, M. et al. (2017) Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? J Clin Microbiol 55 (2), 638-640. |
Number | Date | Country | |
---|---|---|---|
20190338241 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
62667534 | May 2018 | US |